Related Experiment Videos
What are the prospects for regulation in immunotoxicology?
1Division of Special Pathogen and Immunologic Drug Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, MD 20857, USA. hastingsk@cder.fda.gov
Abstract:
Evaluating the immunotoxic potential of investigational new drugs is a standard component of non-clinical safety assessment. Effects evaluated include the potential for drugs to induce hypersensitivity and/or autoimmune reactions or to produce unintended immunosuppression. The Center for Drug Evaluation and Research (CDER) is considering approaches for evaluating potential immunotoxicity. In particular, two methods are being examined for potential recommendation where indicated: immune cell phenotype determination and the murine local lymph node assay. Issues concerning immunotoxicology testing will be discussed.
Insights
Evaluating drug immunotoxicity is crucial for non-clinical safety assessment. The Center for Drug Evaluation and Research (CDER) is examining immune cell phenotyping and the murine local lymph node assay for potential recommendations.
Area of Science:
- Pharmacology
- Toxicology
- Immunology
Background:
- Assessing the immunotoxic potential of new drugs is a standard part of non-clinical safety evaluations.
- Key concerns include drug-induced hypersensitivity, autoimmune reactions, and unintended immunosuppression.
Purpose of the Study:
- To discuss approaches for evaluating potential drug immunotoxicity.
- To examine two specific methods for potential recommendation: immune cell phenotype determination and the murine local lymph node assay.
Main Methods:
- Review of current practices in non-clinical drug safety assessment.
- Examination of immune cell phenotype determination techniques.
- Evaluation of the murine local lymph node assay (mLyNA) for immunotoxicity testing.
Main Results:
- The Center for Drug Evaluation and Research (CDER) is actively considering new methodologies.
- Immune cell phenotyping and mLyNA are under review for potential regulatory recommendation.
- Discussion of various issues pertinent to immunotoxicology testing strategies.
Conclusions:
- Standardized methods for assessing drug immunotoxicity are essential for drug development.
- CDER's evaluation of immune cell phenotyping and mLyNA aims to refine non-clinical safety assessments.
- Further discussion and validation are needed to finalize recommended immunotoxicology testing protocols.